Search
for
Sort by
Research 691–720 of 1000+
- Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359
- ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
- An Update on Plant Derived Anti-Androgens
- Decreased fertility in male rats administered the 5α-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation
- Recent advances in thiasteroids chemistry
- Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands
- Epitestosterone—an endogenous antiandrogen?
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Azasteroids as inhibitors of testosterone 5α-reductase in mammalian skin
- Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
- Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
- Characteristics of flutamide action on prostatic and testicular functions in the rat
- The Double Edge Sword of Testosterone’s Role in the COVID-19 Pandemic
- Nonsteroidal Selective Androgen Receptors Modulators (SARMs): Designer Androgens with Flexible Structures Provide Clinical Promise
- Androgenetic alopecia as an early marker of benign prostatic hyperplasia
- Androgen antagonists in androgen target tissues
- Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity
- Roles of Type 10 17beta-Hydroxysteroid Dehydrogenase in Intracrinology and Metabolism of Isoleucine and Fatty Acids
- Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease
- Testosterone therapy in men: Clinical and pharmacological perspectives
- Dutasteride for the treatment of benign prostatic hyperplasia
- Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats
- Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in the Male
- Finasteride: The First 5α-Reductase Inhibitor
- Synthesis and Evaluation of 2‘-Substituted 4-(4‘-Carboxy- or 4‘-carboxymethylbenzylidene)-<i>N</i>-acylpiperidines: Highly Potent and in Vivo Active Steroid 5α-Reductase Type 2 Inhibitors
- Meta-Analysis of Randomized Clinical Trials of Finasteride
- Corn silk extract improves benign prostatic hyperplasia in experimental rat model
- Anti-Androgen Effects of Extracts and Compounds from<i>Ganoderma lucidum</i>
- Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
- Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors